

Cite this: *J. Mater. Chem. B*, 2023, **11**, 11544

## Hierarchical peroxiredoxin assembly through orthogonal pH-response and electrostatic interactions†

Eduardo Anaya-Plaza,<sup>a</sup> Zual Özdemir,<sup>b</sup> Zdenek Wimmer<sup>b</sup> and Mauri A. Kostianen<sup>a</sup>

Morpheins are proteins that adapt their morphology and function to the environment. Therefore, their use in nanotechnology opens up the bottom-up preparation of anisotropic metamaterials, based on the sequential use of different stimuli. A prominent member of this family of proteins is peroxiredoxins (**Prx**), with dual peroxidase and chaperone function, depending on the pH of the media. At high pH, they show a toroidal morphology that turns into tubular stacks upon acidification. While the toroidal conformers have been explored as building blocks to yield 1D and 2D structures, the obtention of higher ordered materials remain unexplored. In this research, the morphein behaviour of **Prx** is exploited to yield columnar aggregates, that are subsequently self-assembled into 3D anisotropic bundles. This is achieved by electrostatic recognition between the negatively charged protein rim and a positively charged porphyrin acting as molecular glue. The subsequent and orthogonal input lead to the alignment of the monodimensional stacks side-by-side, leading to the precise assembly of this anisotropic materials.

Received 20th February 2023,  
Accepted 13th November 2023

DOI: 10.1039/d3tb00369h

rsc.li/materials-b

## Introduction

Nature has developed, by means of selection and evolution, highly specialised biomolecules to address a plethora of functions and processes. Among them, proteins arise as a versatile and multifunctional family, performing structural, recognition, transport, and catalytic tasks. Interestingly, a selected group of proteins has evolved to fulfil more than one task.<sup>1</sup> For instance, morpheins are proteins that, upon external stimuli (temperature, pH, ionic strength, or oxidating/reducing agents), undergoes conformational changes on the secondary and ternary structure. These environmentally triggered changes have a direct impact on the quaternary structure, thus dictating the protein morphology and function. A prominent example of morpheins are peroxiredoxins (**Prx**).<sup>2,3</sup> These ubiquitous proteins have a primary peroxidase activity based on cysteine chemistry.<sup>4,5</sup> In reducing conditions, the **Prx** homodimer forms a (do)decamer named low molecular weight (LMW) ring. Upon certain *in vivo* or *in vitro* stimuli, co-facial dimers, trimers, and

higher stacks are formed (also known as high molecular weight (HMW) stacks). These are found to act as chaperones, ensuring the correct folding of other proteins. The exploitation of the dual and orthogonal functionality (*i.e.* structural-functional) in bioinspired materials is an exciting avenue, taking advantage of the ready-optimized building blocks from nature.

Highly-ordered protein assemblies have received growing interest as bottom-up strategy to yield biodegradable and biocompatible materials.<sup>6–9</sup> Their well-defined structure, presenting precisely positioned building blocks and regular pore sizes enables technologies such as metamaterial preparation,<sup>10–16</sup> catalytic systems,<sup>17,18</sup> templated (porous) materials,<sup>19,20</sup> biomedical applications,<sup>21</sup> and waste-water treatment.<sup>22</sup> The potential **Prx** have not been missed in this approach.<sup>23</sup> The monomeric ring, as well as other toroidal proteins such as stable protein one (SP1), GroEL, or tobacco mosaic virus (TMV) toroids has been applied as building block for discrete aggregates,<sup>24,25</sup> 1D,<sup>26–34</sup> or 2D assemblies.<sup>35–37</sup> However, preparation of well-defined 3D structures, while explored for other toroids,<sup>38</sup> remains a challenge for peroxiredoxins.

Among the different building blocks employed in protein self-assembly, and electrostatic self-assembly in particular, porphyrinoids are highly versatile.<sup>39</sup> They have been shown to direct the assembly of other proteins such as protein cages<sup>40</sup> or virus-like particles.<sup>41</sup> The main representative of the family, porphyrins (Por) are broadly applied in fields ranging from biomedical to catalysis.<sup>42–44</sup> Their chemical structure, based on

<sup>a</sup> Department of Bioproducts and Biosystems, School of Chemical Engineering, Aalto University, Kemistintie 1, Finland. E-mail: eduardo.anaya@aalto.fi, mauri.kostianen@aalto.fi

<sup>b</sup> Department of Chemistry of Natural Compounds, University of Chemistry and Technology in Prague, Technická 5, 16628 Prague 6, Czech Republic

† Electronic supplementary information (ESI) available: Chemical characterization and supplementary micrographs. See DOI: <https://doi.org/10.1039/d3tb00369h>



a tetrapyrrolic ring, can host a range of metals in their inner cavity. Their optical properties can be finely tuned, showing a wide absorption spectrum ranging from the ultraviolet to the near-infrared region.<sup>45–48</sup> Their excitation leads to emitting properties (e.g. fluorescence) or intersystem crossing that further lead to optoelectronics or singlet oxygen generation.

In this manuscript, we take advantage of the morpheine behaviour of **Prx** to prepare 1D assemblies and subsequently assemble them through orthogonal electrostatic interactions. This is achieved by employing a positively charged Por to mediate the hierarchical self-assembly of **Prx** into highly ordered and anisotropic 3D bundles.

## Materials and methods

### Methods

The <sup>1</sup>H NMR and the <sup>13</sup>C NMR spectra were recorded on a Bruker AVANCE 600 MHz spectrometer at 600.13 MHz and 150.90 MHz, respectively, in deuteriochloroform or deuterium oxide. Tetramethylsilane was used as an internal reference  $\delta = 0.0$ . The <sup>1</sup>H NMR data is presented in the following order: chemical shift ( $\delta$ ) expressed in ppm, multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; and bs, broad singlet), coupling constants in Hertz (Hz), and number of protons. Samples were prepared by dissolving the solids directly into the deuterated solvents in concentrations of ca. 1 mM.

Infrared spectra (IR) were measured using a Nicolet iS5 FT-IR spectrometer with the Attenuated Total Reflection (ATR) method. Peak intensity is noted as strong (s), medium (m), and weak (w). Samples were measured as neat solids through the aforementioned ATR method.

Mass spectra (MS) were measured with a Waters ZMD mass spectrometer in ESI mode (from solution in acetonitrile and catalytic amounts of formic acid) or with an Autoflex Speed MALDI-TOF/TOF mass spectrometer (Bruker Daltonics), of 2,5-dihydroxybenzoic acid as matrix, acetonitrile/water/trifluoroacetic acid (1:1:0.001). External calibration was carried out using peptide calibration standard II (Bruker Daltonics). The mass spectra were manually collected by Flex Control software (version 3.4, Bruker Daltonics) in reflector positive mode at the range of 700–4500 Da. Individual spectra acquired on at least ten different position of sample crystals were summarized to one resulting spectrum for each sample. The resulting spectrum was then processed in mMass software 5.5.0.<sup>49</sup>

**Dynamic light scattering (DLS).** The hydrodynamic diameter ( $D_h$ ) of the assemblies was measured using a Malvern Instruments DLS device (Zetasizer Nano ZS Series) with a 4 mW He–Ne ion laser at a wavelength of 633 nm and an avalanche photodiode detector at an angle of 173°. All experiments were carried at room temperature. PMMA cuvettes were used. Zetasizer software (Malvern Instruments) was used to obtain the particle size distributions.

Solutions of 0.1 mg mL<sup>-1</sup> of **Prx** were prepared diluting from a stock solution in MilliQ water into buffer (20 mM HEPES, 2 mM of TCEP) at the selected pH (from pH 4 to 8), and small

aliquots of **1** were added. Dilution correction was not performed, given the small overall dilution factor (typically less than 5%). Following, the final sample was titrated with 0.01–0.5 M NaCl to disassemble the complex. Beam position, attenuators, and experiment acquisition time was fixed through the experiment.

The molar concentration **Prx** has been determined by either using the calculated extinction coefficient of ( $\epsilon_{280\text{nm}} = 11\,375$ ) or with the molecular weight of 23 300 Da.

Electrostatic potential surface calculation. The electrostatic potential of **Prx** at different pH has been calculated with the help of the APBS web service.<sup>50</sup>

Transmission electron microscopy (TEM) images were taken using a FEI Tecnai 12 Bio-Twin instrument operated at an acceleration voltage of 120 kV. Further, the images were processed using Gatan Digital Micrograph software. The TEM samples were prepared on Formvar carbon coated copper grids (400 mesh, Electron Microscopy Sciences) and plasma cleaned for 20 seconds using a Gatan Solarus. Samples were stained with uranyl formate 2%.

The samples were prepared by either depositing a **Prx** solution (0.1 mg mL<sup>-1</sup>) in the selected buffer, or a mixture of **Prx/1** (0.1 : 0.2 mg mL<sup>-1</sup>) and incubated overnight at +4 °C. 3  $\mu$ L of the sample solution was applied on the carbon-coated side of the grid for 45 seconds. After the incubation, the excess solution was drained from the edge using filter paper. First, the grid was immersed into a 5  $\mu$ L droplet of uranyl formate solution, and excess liquid was directly drained off from the edge using filter paper, followed by a subsequent immersion into a 20  $\mu$ L droplet of uranyl formate solution. The excess amount of stain was removed after 45 seconds from the edge of the grid using filter paper. After this process, the grid was dried at room temperature for at least 30 minutes before imaging.

### Materials

Human peroxiredoxin III (**Prx**) was purchased from ABCAM (UK). All chemicals were purchased from commercial sources in analytical grade, and the solvents were purified by general methods before use: 5,10,15,20-tetrakis(4-hydroxyphenyl)-21H,23H-porphyrin (**P**) ((75%), Aldrich Chemistry (CZ)), propargyl chloride (Merck/Sigma Aldrich (CZ)), potassium carbonate (Penta (CZ)), TBTA (tris((1-benzyl-4-triazolyl)methyl)amine) (Bioconjugate Chemistry (USA)), sodium ascorbate 98% (Merck/Sigma Aldrich (CZ)), CuSO<sub>4</sub>·5H<sub>2</sub>O 98% (Merck/Sigma Aldrich (CZ)), 1 M HCl (g) in EtOAc (Acros Organics (BE)), Zn(OAc)<sub>2</sub> (Merck/Sigma Aldrich (CZ)). Silica gel 60 (0.063–0.200 mm) from Merck (CZ) was used for column chromatography. Thin layer chromatography (TLC) was carried out on silica gel plates (Merck 60F254; CZ), and the visualization was performed by ultraviolet (UV) detection and by spraying with a methanolic solution of phosphomolybdic acid (5%) followed by heating.

### Synthesis of tetracationic Por 1

**5,10,15,20-Tetrakis[4-(prop-2-yn-1-yloxy)phenyl]porphyrin (2).** Propargyl chloride (852  $\mu$ L, 11.8 mmol) and grinded K<sub>2</sub>CO<sub>3</sub> (1.65 g, 12.0 mmol) were added to a solution of **P** (1 g, 1.5 mmol) in DMF/toluene (20/10 mL). The mixture was stirred in the



absence of light at 120 °C under argon for 15 min. The reaction was monitored using TLC, and till complete conversion of the starting materials to product, additional amount of propargyl chloride was added. Upon complete of reaction (after 1 week), it was quenched by adding water. The reaction mixture was extracted into EtOAc and washed with water using a separatory funnel. The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and removed under vacuum to obtain the crude product. The crude product was column purified on silica gel using 50/50 v/v (%) petroleum ether/chloroform to 100% chloroform. The obtained product, recrystallized from a DCM/MeOH mixture, afforded **2** in 84% yield as a purple solid. FT-IR (KBr):  $\nu$  [cm<sup>-1</sup>] 3291 (w)  $\nu$ (NH), 3212 (w)  $\nu$ (CH) ( $\equiv$ CH), 2923 (w), 2359 (w), 2342 (w), 2112 (m)  $\nu$ (C $\equiv$ C), 1605 (s), 1603 (s), 1498 (s), 1471 (s), 1381 (m)  $\delta_s$ (CH<sub>3</sub>), 1349 (m)  $\delta_s$ (CH<sub>3</sub>), 1288 (m)  $\nu$ (C-O), 1213 (s), 1173 (s)  $\nu$ (C-O), 1109 (m), 1024 (s), 980 (m), 964 (s), 925 (m), 843 (m), 800 (s), 786 (s), 734 (s), 660 (m)  $\gamma$ (CH) ( $\equiv$ CH), 539 (s), 484 (m). MS ( $m/z$ ): 831.0 [M + H]<sup>+</sup> (ESI<sup>+</sup>, coin voltage 30 V). <sup>1</sup>H NMR (600.13 MHz, CDCl<sub>3</sub>):  $\delta$  [ppm] 8.80 (bs, 1H, 3-CH), 8.07–8.10 (m, 1H, 6-CH), 7.29–7.32 (m, 1H, 7-CH), 4.92 (d, 2H,  $J$  = 2.5 Hz, 9-CH<sub>2</sub>), 2.63 (t, 1H,  $J$  = 2.5 Hz, 11-CH), 2.83 (bs, 1H, NH). <sup>13</sup>C NMR (150.92 MHz, CDCl<sub>3</sub>):  $\delta$  [ppm] 129.4 (d, C-2), a (C-3), 119.56 (s, C-4), 135.47 (s, C-5), 135.56 (d, C-6), 113.11 (d, C-7), 157.43 (s, C-8), 56.15 (t, C-9), 78.66 (s, C-10), 75.86 (d, C-11).

**Zn(n)[5,10,15,20-tetrakis[4-(prop-2-yn-1-yloxy)phenyl] porphyrin] (3).** Zn(OAc)<sub>2</sub> (2.11 g, 9.62 mmol) in MeOH (50 mL) was added to a stirred solution of **2** (800 mg, 0.9628 mmol) in DCM/CHCl<sub>3</sub> (14/42 mL) in a round-bottom flask and stirred in the absence of light at r.t. for 48 h. The reaction mixture was then extracted into the DCM and washed with water. After drying the organic layer over anhydrous Na<sub>2</sub>SO<sub>4</sub>, the volatiles were removed under reduced pressure. Obtained crude product recrystallized from hot CHCl<sub>3</sub> affording **3** in a 65% yield as a dark purple solid. FT-IR (KBr):  $\nu$  [cm<sup>-1</sup>] 3277 (m)  $\nu$ (CH) ( $\equiv$ CH), 2919 (w), 2359 (m), 2341 (m), 2123 (w)  $\nu$ (C $\equiv$ C), 1600 (m), 1603 (s), 1488 (s), 1375 (m)  $\delta_s$ (CH<sub>3</sub>), 1337 (m)  $\delta_s$ (CH<sub>3</sub>), 1280 (m)  $\nu$ (C-O), 1204 (s), 1173(s)  $\nu$ (C-O), 1108 (m), 1069 (m), 1026 (m), 993 (s), 928 (m), 848 (m), 796 (s), 715 (m), 668 (m)  $\gamma$ (CH) ( $\equiv$ CH), 634 (s), 532 (m), 424 (m). MS ( $m/z$ ): 892.0 [M + H]<sup>+</sup> (ESI<sup>+</sup>, coin voltage 25 V). <sup>1</sup>H NMR (600.13 MHz, CDCl<sub>3</sub>):  $\delta$  [ppm] 8.93 (s, 1H, 3-CH), 8.02–8.13 (m, 1H, 6-CH), 7.29–7.34 (m, 1H, 7-CH), 4.94 (d, 2H,  $J$  = 2.4 Hz, 9-CH<sub>2</sub>), 2.65 (t, 1H,  $J$  = 2.4 Hz, 11-CH). <sup>13</sup>C NMR (150.92 MHz, CDCl<sub>3</sub>):  $\delta$  [ppm] 150.43 (s, C-2), 131.93 (d, C-3), 120.57 (s, C-4), 136.08 (s, C-5), 135.36 (d, C-6), 112.98 (d, C-7), 157.28 (s, C-8), 56.15 (t, C-9), 78.72 (s, C-10), 75.82 (d, C-11).

**Zn(n){tetra-*tert*-butyl[porphyrin-5,10,15,20-tetrayltetrakis(benzene-4,1-diyloxymethanediyl-1*H*-1,2,3-triazole-4,1-diyl-pentane-5,1-diyl)]tetrakis(carbamate)} (4).** Compound **5** (204 mg, 0.89 mmol) (see the preparation below), was added to a stirred solution of **3** (100 mg, 0.11 mmol) in DCM (4.0 mL), followed by a CuSO<sub>4</sub>·5H<sub>2</sub>O/TBTA (1 : 1) complex solution (5.0 mL, 0.22 mmol) and stirred in the absence of light at r.t. for 5 min. To the above mixture, sodium ascorbate (83 mg, 0.42 mmol) was added, and the contents were mixed at r.t. for 19 h. The reaction mixture was then extracted into CHCl<sub>3</sub> and washed with water. After drying

the organic layer over anhydrous Na<sub>2</sub>SO<sub>4</sub>, the volatiles were removed under reduced pressure. The crude product obtained after aqueous workup was column purified on silica gel using ethanol in chloroform [from 100/0 v/v (%) to 100/7 v/v (%) to afford **4** in a 85% yield as a purple solid. FT-IR (KBr):  $\nu$  [cm<sup>-1</sup>] 3322 (w)  $\nu$ (NH), 2330 (w), 1698 (s)  $\nu$ (amide I), 1603 (w), 1506 (m)  $\nu$ (amide II), 1455 (m), 1389 (w)  $\delta_s$ (CH<sub>3</sub>), 1363 (m)  $\delta_s$ (CH<sub>3</sub>), 1242 (s)  $\nu$ (C-O), 1172 (s)  $\nu$ (C-O), 1047 (m), 991 (s), 846 (m), 795 (s), 717 (s). MALDI MS ( $m/z$ ): 1804.93 Da, 1744.02 Da. <sup>1</sup>H NMR (600.13 MHz, CDCl<sub>3</sub>):  $\delta$  [ppm] 8.85 (s, 1H, 3-CH), 8.02–8.05 (m, 1H, 6-CH), 7.25–7.30 (m, 1H, 7-CH), 5.25 (bs, 2H, 9-CH<sub>2</sub>), 7.70 (bs, 1H, 11-CH), 4.27–4.39 (m, 2H, 12-CH<sub>2</sub>), 2.3 (bs, 2H, 13-CH<sub>2</sub>), 1.53–1.62 (m, 2H, 14-CH<sub>2</sub>), 1.94–2.08 (m, 2H, 15-CH<sub>2</sub>), 3.08 (bs, 2H, 16-CH<sub>2</sub>), 1.40 (s, 9H, Boc(CH<sub>3</sub>)). <sup>13</sup>C NMR (150.92 MHz, CDCl<sub>3</sub>):  $\delta$  [ppm] 145.96 (s, C-2), a (d, C-3), 117.69 (s, C-4), 134.10 (s, C-5), a (d, C-6), a (d, C-7), 162.73 (s, C-8), 53.18 (t, C-9), 142.30 (s, C-10), 127.77 (d, C-11), 42.22 (t, C-12), 29.16 (t, C-13), 25.68 (t, C-14), 29.16 (t, C-15), 31.87 (t, C-16).

**5,5',5'',5'''-[Porphyrin-5,10,15,20-tetrayltetrakis(benzene-4,1-diyloxymethanediyl-1*H*-1,2,3-triazole-4,1-diyl)]tetrapentan-1-amine (1).** A solution of HCl (gas; 1.0 M in ethyl acetate; 4.2 mL, 4.20 mmol) was added to a solution of **4** (76 mg, 0.04 mmol), and the reaction mixture was stirred in the absence of light at r.t. for 24 h. The resulting green residue was filtered and washed with diethyl ether and CHCl<sub>3</sub> to furnish **5** as a violet-colored solid in an 80% yield. FT-IR (KBr):  $\nu$  [cm<sup>-1</sup>] 3500–2500 (br)  $\nu$ (NH<sup>+</sup>), 2924 (w), 2360 (m)  $\nu$ (CH), 1602 (s) (triazole ring), 1498 (s)  $\delta_s$ (CH<sub>3</sub>),  $\beta_s$ (CH<sub>2</sub>), (triazole ring), 1344 (m), 1215 (sh), 1174 (m)  $\nu$ (C-O), 996 (s), 797 (s), 715 (w). MALDI MS ( $m/z$ ): 1343.68 Da. <sup>1</sup>H NMR (600.13 MHz, D<sub>2</sub>O):  $\delta$  [ppm] 7.30–7.85 (s, 1H 3-CH), 7.30–7.85 (m, 1H, 6-CH), 7.30–7.85 (m, 1H, 7-CH), 5.57 + 5.71 (m, 2H, 9-CH<sub>2</sub>), 8.36 (s, 1H, 11-CH), 4.65–4.72 (m, 2H, 12-CH<sub>2</sub>), 2.18–2.30 (m, 2H, 13-CH<sub>2</sub>), 1.60–1.75 (m, 2H-14-CH<sub>2</sub>), 1.94–2.08 (m, 2H, 15-CH<sub>2</sub>), 3.20–3.35 (bs, 2H, 16-CH<sub>2</sub>). <sup>13</sup>C NMR (150.92 MHz, CDCl<sub>3</sub>):  $\delta$  [ppm] 150.24 (s, C-2), 131.47 (d, C-3), 120.02 (s, C-4), 135.48 (s, C-5), 136.44 (d, C-6), 112.73 (d, C-7), 156.22 (s, C-8), 62.14 (t, C-9), 144.12 (s, C-10), 122.67 (d, C-11), 50.27 (t, C-12), 29.72 (t, C-13), 23.57 (t, C-14), 29.33 (t, C-15), 39.93 (t, C-16), 157.73 (s, -COOC(CH<sub>3</sub>)<sub>3</sub>), 79.29 (s, -COOC(CH<sub>3</sub>)<sub>3</sub>), 28.27 (q, -COOC(CH<sub>3</sub>)<sub>3</sub>).

***tert*-(Butyl (5-azidopentyl)carbamate) (5).** Imidazole-1-sulfonyl azide hydrogen sulfate (647 mg, 2.39 mmol), prepared as reported,<sup>51</sup> was added to a mixture of the commercially available *N*-boc cadaverine (1.0 g), K<sub>2</sub>CO<sub>3</sub> (0.5 mmol), and CuSO<sub>4</sub>·5H<sub>2</sub>O (5 mg, 0.02 mmol) in methanol (22 mL), and the resulting reaction mixture was stirred at r.t. for 30 h. It was diluted with H<sub>2</sub>O (50 mL) and extracted with ethyl acetate (3 × 50 mL). After drying the organic layers over anhydrous Na<sub>2</sub>SO<sub>4</sub>, the volatiles were removed under reduced pressure. The crude products obtained after aqueous workup were column purified on silica gel using ethanol in chloroform [from 100/0 v/v (%) to 100/2 v/v (%) to afford **5** in 90% yield as oily liquid. FT-IR (KBr):  $\nu$  [cm<sup>-1</sup>] 2976 (m), 2936 (m)  $\nu$ (CH), 2098 (m)  $\nu$ (N $\equiv$ N), 1693 (s)  $\nu$ (amide I), 1519 (m)  $\nu$ (amide II), 1445 (m), 1390 (m), 1366 (m)  $\delta$ (CH<sub>3</sub>), 1250 (m), 1175 (s)  $\nu$ (C-O), 766 (s). MS ( $m/z$ ): 251.1 [M + Na]<sup>+</sup> (ESI<sup>+</sup>, coin voltage 20 V), 255.1 (ESI<sup>-</sup>, coin voltage 20 V). <sup>1</sup>H NMR (600.13 MHz, CDCl<sub>3</sub>):  $\delta$  [ppm] 3.24 (bdt, 2H,  $J$  = 4.7, 5.4,



5.4 Hz, 1-CH<sub>2</sub>), 1.41–1.45 (m, 2H, 2-CH<sub>2</sub>), 1.26–1.33 (m, 2H, 3-CH<sub>2</sub>), 1.50–1.58 (m, 2H, 4-CH<sub>2</sub>), 3.35 (t, 2H, 5-CH<sub>2</sub>), 1.38 (s, 3H, Boc (CH<sub>3</sub>)). <sup>13</sup>C NMR (150.90 MHz, CDCl<sub>3</sub>): δ [ppm] 40.03 (t, C-1), 29.64 (t, C-2), 23.91 (t, C-3), 28.39 (t, C-4), 51.23 (t, C-5), 155.74 (s, -COOC(CH<sub>3</sub>)<sub>3</sub>), 79.81 (s, -COOC(CH<sub>3</sub>)<sub>3</sub>), 28.32 (q, -COOC(CH<sub>3</sub>)<sub>3</sub>), 4.77 (bs, 1H, NH).

## Results and discussion


### pH dependence of building blocks

The morphein behaviour of human peroxiredoxin 3 (**Prx**, Fig. 1a) was characterized by means of TEM. Solutions of 0.1 mg mL<sup>-1</sup> of protein were diluted from a stock solution in Milli-Q water into a final buffer of HEPES (20 mM) and a reducing agent tris((2-carboxyethyl)phosphine) (TCEP, 2 mM) with varying pH. At pH 8, **Prx** forms toroidal dodecamers (Fig. 1a and b) of 12 nm in diameter, with internal pores of 6 nm.<sup>52,53</sup> Upon acidification, dimers and oligomers formed by co-facial stacking are found (pH 6, Fig. 1c), with the length increasing to tubules at pH 4 (Fig. 1d and e). The stacking is likely consequence of burying the hydrophobic patches between dodecamers, as well as polar interactions.<sup>54</sup> A closer look to the calculated electrostatic surface potential at pH 8 shows an overall negative charge (in red) distributed both on the toroidal surface and the rim (Fig. 1f, left, top and bottom respectively). Close to the pI (5.9 for **Prx**), an even distribution of positive and negative charges are found over all surfaces. As expected, at

pH 4 a major component of positive charges (blue) is found. However, it is worth mentioning that upon ring stacking, only the outer rim is available to interact, and it shows apical patches of negative charges.

A tetracationic Por (**1**) was synthesized (Fig. 1g, see the ESI† for detailed protocol and characterization). Briefly, the (C8)-OH groups on the commercially available P ring were first substituted with propargyl chloride in the presence of K<sub>2</sub>CO<sub>3</sub> to furnish **2**. Compound **2** was then reacted with Zn(OAc)<sub>2</sub> to obtain the metalated Zn(II)Por **3**. The chelation step with Zn(II) was necessary, to protect the inner ring from sequestering Cu(II) from the Cu(I)-catalyzed Huisgen 1,3-dipolar cycloaddition reaction (CuAAC). Accordingly, **4** was prepared by appending the *tert*-butoxy (Boc)-protected azide derivative of cadaverine (**5**) using the previously described CuAAC method (Scheme S2, ESI†).<sup>55</sup> Acid hydrolysis of **4** using 1.0 M HCl (gas) in ethyl acetate removed Zn(II) and Boc-protecting groups simultaneously, and **1** was obtained. All the intermediates and final products were characterized by NMR, mass and FTIR (see ESI†).

Bearing four primary amines, the overall charge and therefore aqueous solubility is expected to vary with the pH. Therefore, the absorption spectra was recorded at varying pH (Fig. 1h). At high pH, broad peaks and features are found in the Soret band (400–450 nm), consistent with aggregation and loss in solubility upon deprotonation of the primary amines (pK<sub>a</sub> 8.9). Upon acidification, the Soret band exhibits a blue-shift and remains constant upon pH 4, where it undergoes a sharp red-shift and, more clearly, a Q-band appears at 680 nm,



**Fig. 1** Building blocks and their pH-dependent properties. (a) Structure of the human peroxiredoxin III (**Prx**), PDB ID: 5UCX). Protein dimers are shown in alternating blue and magenta colours, forming a dodecamer. TEM images of **Prx** in 20 mM HEPES, 2 mM TCEP at pH 8 (b), pH 6 (c) and pH 4 (d), showing discrete rings, short, and long tubular stacks, respectively. (e) Detailed micrograph of fourteen stacked rings at pH 4, showing co-facial aggregation. (f) Isoelectric surfaces calculated at pH 8, 6 and 4 (left to right) of **Prx**. (g) Chemical structure of cationic Por **1**, showing four positive charges in its hydrochloric form. (h) Absorption spectra of **1** at varying pH, showing clear changes in the Soret band (350–420 nm) and Q band(s) (520–700 nm). (i) pH dependence of the Soret band at 410 and 427 nm, showing clear transitions between protonated cavity (pH < 4), acidic form (4 < pH < 10), and basic form inducing aggregation (pH > 10).




indicating a protonation of the inner cavity of the Por.<sup>56</sup> The trend is clearly observed by plotting the absorbance at 410 and 427 nm depending on the pH (Fig. 1i), depicting the three regimes. As expected, **1** shows good and stable aqueous solubility in the pH regime studied for the **Prx**. This assignment is in good agreement with previously reported spermine-substituted Por.<sup>54</sup>

### Electrostatic assembly of hybrids

The electrostatic self-assembly of **Prx** and Por was characterized by dynamic light scattering (DLS), in the range of pH suitable for **1** ( $4 < \text{pH} < 8$ ). At pH 8, **Prx** shows an apparent hydrodynamic diameter ( $D_h$ ) of  $12 \pm 3$  nm, corresponding well with the monomeric toroidal protein (Fig. 2a and Table S1, ESI<sup>†</sup>). Upon titration with **1**, a sharp decrease of scattering from monomeric toroid is observed, followed up by an increase in  $> 1000$  nm species, which corresponds to large complexes. This is likely consequence of the strong electrostatic interaction between highly charged **Prx** and **1**. At pH 6 (Fig. 2b), the monomer peak slowly shifts to higher  $D_h$ , showing at the same time the appearance of large complexes. The more stepwise interaction can be explained by a hindered electrostatic interaction. Last, at pH 4, only medium size aggregates can be found (*ca.* 50 nm) together with larger-sized complexes. Upon titration

with **1**, a minor decrease in the medium size complexes is observed, hinting a limited interaction between the now overall positively charged protein and dye. While this information is a clear sign of electrostatic recognition leading to aggregation, the calculated  $D_h$  can only be interpreted qualitatively given the large size as well as the expected non-spherical (rod-like) shape at pH 6 and 4. Additionally, the derived count rate gives a calculated count of photons scattered by the sample. Following the Stokes–Einstein equation, and assuming no significant dilution of protein or variation in the refractive index or viscosity through the titration, an increase of the derived count rate is consequence of the increase in diffusion coefficient and, therefore, particle size. In the **Prx** titration with **1** (Fig. 2d) we observe at pH 8 the derived count rate to sharply increase around  $3 \times 10^{-6}$  M, saturating at  $2 \times 10^{-5}$  M.

At pH 6, a more modest and milder increase is observed. At pH 4, no noticeable increase was found in the range explored. A diagram prepared by measuring the derived count rate of a constant **Prx** concentration ( $0.1 \text{ mg mL}^{-1}$ ) as a function of pH and ratio of **1**, shows that the regions with highest binding affinity are located between pH 7.5 and 6.5, and  $[\mathbf{1}]$  between 50 to 200 equivalents (Fig. 2e, green area). In order to show the electrostatic character of the interaction, **Prx-1** complexes of constant concentration ( $[\mathbf{Prx}] = 0.1 \text{ mg mL}^{-1}$ ,



**Fig. 2** Self-assembly of **Prx-1** complexes by dynamic light scattering (DLS). Titration of  $[\mathbf{Prx}] = 0.1 \text{ mg mL}^{-1}$  with increasing concentrations of **1**, given as volume-averaged size distributions at (a) pH 8, (b) pH 6, and (c) pH 4. (d) Derived count rate, showing a sharp increase upon formation of large complexes. (e) Diagram of complex formation at different pH and **1** ratios. (f) Complex disassembly upon increase of the ionic strength of the media, achieved by NaCl concentration. (g) Phase diagram of disassembly at different pH and NaCl concentration.






Fig. 3 Morphology of the **Prx-1** complexes. TEM micrographs of the hybrids at (a) pH 8, (b) pH 6, and (c) pH 4. Inset: Close-up of the bundle. Samples prepared by pH adjustment in HEPES 20 mM, TCEP 2 mM. [**Prx**] = 0.1 mg mL<sup>-1</sup> and [**1**] = 0.2 mg mL<sup>-1</sup>. (d) Schematic representation of the two step process.

[**1**] =  $5 \times 10^{-5}$  M) were titrated with NaCl. The increase of the ionic strength screens the electrostatic interactions, effectively disassembling the complexes. At pH 8, the strong interaction is not fully reversed until 500 mM of NaCl. At pH 6, the interaction is screened at 200 mM, confirming the weaker electrostatic interaction. At pH 4 the same trend is observed, with a modest yet noticeable drop at the same NaCl concentration. Like the binding experiment, a diagram of the disassembly mediated by ionic strength was prepared at different pH values (Fig. 2g). The data shows the expected trend of stronger electrostatic interaction at higher pH.

### Morphology of the complexes

A fine control on the binding affinity is a key parameter to obtain highly ordered assemblies: high binding affinities lead to low order/amorphous aggregates, and low affinities to no recognition, moderate affinities are desirable to yield well ordered structures.<sup>57</sup> In high binding affinity regime (pH 8), the strong interaction leads to clusters of toroidal proteins with no apparent orientation as shown by TEM images (Fig. 3a and Fig. S1, ESI<sup>†</sup>). This is in agreement with the overall negative charge of **Prx** (see Fig. 1f), that is well accessible in the monomer and upon interaction with **1**. Therefore, since the protein shows no preferential binding direction, it leads to random aggregation. At pH 6, showing a milder binding affinity, clusters of short and partially aligned tubules are observed (Fig. 3b and Fig. S2, ESI<sup>†</sup>). Last, at pH 4, large structures of well-aligned tubes of **Prx-1** hybrids are found (Fig. 3c and Fig. S3, ESI<sup>†</sup>). With typical widths of *ca.* 100 nm and lengths at the micron range, the tightly packed bundles consist of approximately eight **Prx** proteins in diameter, and hundreds stack. The envisioned mechanism of formation has two steps: first tubule formation is controlled by pH, followed by bundling effect caused by electrostatic interaction with **1**. This highly ordered structure is likely a consequence of two factors: (i) the tubule stacking masks the more positively charged surface, and (ii) the remaining negative charge remains on the toroidal rim, enabling a side-by-side interaction of the tubes. The orientation of **1** at the protein interphase is likely random in the pH range explored, given the small size of **1** compared to **Prx** and the high degree of freedom of the charged side chains. It is worthy to mention that these

morphologies are the result of a delicate interplay of forces and, subsequently, small deviations in ionic strength or the absence of reducing agents as TCEP yields amorphous aggregation.

## Conclusions

In this manuscript, we report an orthogonal approach towards highly ordered biohybrid materials. We exploit the biological versatility of morpheein proteins to direct the assembly in one direction as tubular stacks, to subsequently tune the electrostatic interactions of the rim to direct the assembly orthogonally. First, we delimited the pH functional range for both moieties, then explore their interaction, based on electrostatic interaction. Last, the morphology of the hybrids was characterized by microscopy techniques. At high pH, strong binding affinities are found, although it leads to poor control and amorphous aggregation. Close to the isoelectric point of the protein, the interaction is moderate, and some order in form of clumped tubules is found. Finally, at pH 4, highly ordered structures are found, directed by the mildest interactions. Our approach, based on the ubiquitous electrostatic interaction to post-functionalize protein cage stacks, shows tremendous potential to be applied in other 1D protein stacks. This opens the toolbox of interactions for protein cage self-assembly, facilitating the often challenging preparation of anisotropic biohybrid materials. These types of materials have the advantage of high directionality and biocompatibility, rendering unique candidates for their exploitation in tissue engineering (*e.g.* aligning cell growth) or, when doped with conducting (nano)materials, suitable for sensors and wearable electronics.<sup>15</sup>

## Author contributions

The authors contributed the following: E. A.-P. biohybrid formation and characterization, project design, funding acquisition, drafting. Z. Ö. Synthesis and characterization. W. Z. Drafting. M. A. K.: project design, drafting.

## Conflicts of interest

There are no conflicts to declare.



## Acknowledgements

We acknowledge the funding from the Marie Skłodowska-Curie grant (794536), Academy of Finland (projects 308578, 303804, 267497, 341057), Jane and Aatos Erkkö Foundation. We acknowledge the provision of facilities and technical support by Aalto University Bioeconomy Facilities and OtaNano-Nanoscience Center (Aalto-NMC).

## Notes and references

- 1 A. F. Dishman and B. F. Volkman, *ACS Chem. Biol.*, 2018, **13**, 1438–1446.
- 2 Z. A. Wood, E. Schröder, J. R. Harris and L. B. Poole, *Trends Biochem. Sci.*, 2003, **28**, 32–40.
- 3 M. Aran, D. Ferrero, A. Wolosiuk, S. Mora-García and R. A. Wolosiuk, *J. Biol. Chem.*, 2011, **286**, 23441–23451.
- 4 M. E. Conway and C. Lee, *Biomol. Concepts*, 2015, **6**, 269–284.
- 5 F. Angelucci, A. Bellelli, M. Ardini, R. Ippoliti, F. Saccoccia and V. Morea, *FEBS J.*, 2015, **282**, 2827–2845.
- 6 A. Korpi, E. Anaya-Plaza, S. Välimäki and M. Kostiaainen, *Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol.*, 2020, **12**, e1578.
- 7 Q. Luo, C. Hou, Y. Bai, R. Wang and J. Liu, *Chem. Rev.*, 2016, **116**, 13571–13632.
- 8 J. R. McMillan, O. G. Hayes, P. H. Winegar and C. A. Mirkin, *Acc. Chem. Res.*, 2019, **52**, 1939–1948.
- 9 N. P. King, J. B. Bale, W. Sheffler, D. E. McNamara, S. Gonen, T. Gonen, T. O. Yeates and D. Baker, *Nature*, 2014, **510**, 103–108.
- 10 J. Sun, C. DuFort, M. C. Daniel, A. Murali, C. Chen, K. Gopinath, B. Stein, M. De, V. M. Rotello, A. Holzenburg, C. C. Kao and B. Dragnea, *Proc. Natl. Acad. Sci. U. S. A.*, 2007, **104**, 1354–1359.
- 11 V. Liljeström, A. Ora, J. Hassinen, H. T. Rekola, N. Nonappa, M. Heilala, V. Hynninen, J. J. Joensuu, R. H. A. Ras, P. Törmä, O. Ikkala and M. A. Kostiaainen, *Nat. Commun.*, 2017, **8**, 671.
- 12 M. Künzle, T. Eckert and T. Beck, *J. Am. Chem. Soc.*, 2016, **138**, 12731–12734.
- 13 M. Lach, C. Strelow, A. Meyer, A. Mews and T. Beck, *ACS Appl. Mater. Interfaces*, 2022, **14**, 10656–10668.
- 14 N. P. King, W. Sheffler, M. R. Sawaya, B. S. Vollmar, J. P. Sumida, I. André, T. Gonen, T. O. Yeates and D. Baker, *Science*, 2012, **336**, 1171–1174.
- 15 J. B. Bale, S. Gonen, Y. Liu, W. Sheffler, D. Ellis, C. Thomas, D. Cascio, T. O. Yeates, T. Gonen, N. P. King and D. Baker, *Science*, 2016, **353**, 389–394.
- 16 J. Laniado, K. A. Cannon, J. E. Miller, M. R. Sawaya, D. E. McNamara and T. O. Yeates, *ACS Nano*, 2021, **15**, 4277–4286.
- 17 E. Selivanovitch, M. Uchida, B. Lee and T. Douglas, *ACS Nano*, 2021, **15**, 15687–15699.
- 18 M. Lach, M. Künzle and T. Beck, *Chem. – Eur. J.*, 2017, **23**, 17482–17486.
- 19 A. Korpi and M. A. Kostiaainen, *ChemNanoMat*, 2022, **8**, e202100458.
- 20 Y. T. Lai, E. Reading, G. L. Hura, K. L. Tsai, A. Laganowsky, F. J. Asturias, J. A. Tainer, C. V. Robinson and T. O. Yeates, *Nat. Chem.*, 2014, **6**, 1065–1071.
- 21 E. Anaya-Plaza, A. Shaukat, I. Lehtonen and M. A. Kostiaainen, *Adv. Healthcare Mater.*, 2021, **10**, 2001162.
- 22 A. Shaukat, E. Anaya-Plaza, N. K. Beyeh and M. A. Kostiaainen, *Chem. – Eur. J.*, 2022, **28**, e202104341.
- 23 M. Ardini, A. Bellelli, D. L. Williams, L. Di Leandro, F. Giansanti, A. Cimini, R. Ippoliti and F. Angelucci, *Bioconjugate Chem.*, 2021, **32**, 43–62.
- 24 E. Miceli, M. Kar and M. Calderón, *J. Mater. Chem. B*, 2017, **5**, 4393–4405.
- 25 G. Giovannini, M. Ardini, N. Maccaferri, X. Zambrana-Puyalto, G. Panella, F. Angelucci, R. Ippoliti, D. Garoli and F. De Angelis, *Adv. Opt. Mater.*, 2020, **8**, 1901583.
- 26 S. Manuguri, K. Webster, N. A. Yewdall, Y. An, H. Venugopal, V. Bhugra, A. Turner, L. J. Domigan, J. A. Gerrard, D. E. Williams and J. Malmström, *Nano Lett.*, 2018, **18**, 5138–5145.
- 27 M. Ardini, F. Giansanti, L. Di Leandro, G. Pitari, A. Cimini, L. Ottaviano, M. Donarelli, S. Santucci, F. Angelucci and R. Ippoliti, *Nanoscale*, 2014, **6**, 8052–8061.
- 28 M. Ardini, J. A. Huang, V. Caprettini, F. De Angelis, F. Fata, I. Silvestri, A. Cimini, F. Giansanti, F. Angelucci and R. Ippoliti, *Biochim. Biophys. Acta, Gen. Subj.*, 2020, **1864**, 129617.
- 29 H. Sun, X. Zhang, L. Miao, L. Zhao, Q. Luo, J. Xu and J. Liu, *ACS Nano*, 2016, **10**, 421–428.
- 30 L. Miao, J. Han, H. Zhang, L. Zhao, C. Si, X. Zhang, C. Hou, Q. Luo, J. Xu and J. Liu, *ACS Nano*, 2014, **8**, 3743–3751.
- 31 L. Zhao, H. Zou, H. Zhang, H. Sun, T. Wang, T. Pan, X. Li, Y. Bai, S. Qiao, Q. Luo, J. Xu, C. Hou and J. Liu, *ACS Nano*, 2017, **11**, 938–945.
- 32 S. Sim, T. Niwa, H. Taguchi and T. Aida, *J. Am. Chem. Soc.*, 2016, **138**, 11152–11155.
- 33 T. Sendai, S. Biswas and T. Aida, *J. Am. Chem. Soc.*, 2013, **135**, 11509–11512.
- 34 J. R. McMillan and C. A. Mirkin, *J. Am. Chem. Soc.*, 2018, **140**, 6776–6779.
- 35 M. Endo, M. Fujitsuka and T. Majima, *Chem. – Eur. J.*, 2007, **13**, 8660–8666.
- 36 J. Zhang, X. Wang, K. Zhou, G. Chen and Q. Wang, *ACS Nano*, 2018, **12**, 1673–1679.
- 37 Y. Li, C. Xia, R. Tian, L. Zhao, J. Hou, J. Wang, Q. Luo, J. Xu, L. Wang, C. Hou, B. Yang, H. Sun and J. Liu, *ACS Nano*, 2022, **16**, 8012.
- 38 O. G. Hayes, B. E. Partridge and C. A. Mirkin, *Proc. Natl. Acad. Sci. U. S. A.*, 2021, **118**, e2106808118.
- 39 V. Almeida-Marrero, E. van de Winckel, E. Anaya-Plaza, T. Torres and A. de la Escosura, *Chem. Soc. Rev.*, 2018, **47**, 7369–7400.
- 40 J. Mikkilä, E. Anaya-Plaza, V. Liljeström, J. R. Caston, T. Torres, A. De La Escosura and M. A. Kostiaainen, *ACS Nano*, 2016, **10**, 1565–1571.



- 41 E. Anaya-Plaza, A. Aljarilla, G. Beaune, Nonappa, J. V. I. Timonen, A. Escosura, T. Torres and M. A. Kostiainen, *Adv. Mater.*, 2019, **31**, 1902582.
- 42 W. R. Osterloh, K. M. Kadish and E. Van Caemelbecke, *Handbook of Porphyrin Science*, World scientific, 2023, vol. 47.
- 43 G. Bottari, O. Trukhina, M. Ince and T. Torres, *Coord. Chem. Rev.*, 2012, **256**, 2453–2477.
- 44 G. Bottari, G. de la Torre, D. M. Guldi and T. Torres, *Coord. Chem. Rev.*, 2021, **428**, 213605.
- 45 J. Chakraborty, I. Nath and F. Verpoort, *Coord. Chem. Rev.*, 2016, **326**, 135–163.
- 46 H. Lu and N. Kobayashi, *Chem. Rev.*, 2016, **116**, 6184–6261.
- 47 Q. Sun, L. M. Mateo, R. Robles, P. Ruffieux, G. Bottari, T. Torres, R. Fasel and N. Lorente, *Adv. Sci.*, 2022, **9**, 2105906.
- 48 Q. Sun, L. M. Mateo, R. Robles, P. Ruffieux, N. Lorente, G. Bottari, T. Torres and R. Fasel, *J. Am. Chem. Soc.*, 2020, **142**, 18109–18117.
- 49 M. Strohalm, D. Kavan, P. Novák, M. Volný and V. Havlíček, *Anal. Chem.*, 2010, **82**, 4648–4651.
- 50 E. Jurrus, D. Engel, K. Star, K. Monson, J. Brandi, L. E. Felberg, D. H. Brookes, L. Wilson, J. Chen, K. Liles, M. Chun, P. Li, D. W. Gohara, T. Dolinsky, R. Konecny, D. R. Koes, J. E. Nielsen, T. Head-Gordon, W. Geng, R. Krasny, G. Wei, M. J. Holst, J. A. McCammon and N. A. Baker, *Protein Sci.*, 2018, **27**, 112–128.
- 51 Z. Özdemir, D. Šaman, K. Bertula, M. Lahtinen, L. Bednářová, M. Pazderková, L. Rárová, Nonappa and Z. Wimmer, *Langmuir*, 2021, **37**, 2693–2706.
- 52 N. A. Yewdall, H. Venugopal, A. Desfosses, V. Abrishami, Y. Yosaatmadja, M. B. B. Hampton, J. A. A. Gerrard, D. C. C. Goldstone, A. K. K. Mitra and M. Radjainia, *Structure*, 2016, **24**, 1120–1129.
- 53 N. A. Yewdall, A. V. Peskin, M. B. Hampton, D. C. Goldstone, F. G. Pearce and J. A. Gerrard, *Biochem. Biophys. Res. Commun.*, 2018, **497**, 558–563.
- 54 F. Angelucci, F. Saccoccia, M. Ardini, G. Boumis, M. Brunori, L. Di Leandro, R. Ippoliti, A. E. Miele, G. Natoli, S. Scotti and A. Bellelli, *J. Mol. Biol.*, 2013, **425**, 4556–4568.
- 55 M. Yang, Z. Özdemir, H. Kim, S. Nah, E. Andris, X. Li, Z. Wimmer and J. Yoon, *Adv. Healthcare Mater.*, 2022, **11**, 2200529.
- 56 J. Sobczyński, H. H. Tønnesen and S. Kristensen, *Pharmazie*, 2013, **68**, 100–109.
- 57 A. M. Kalsin, *Science*, 2012, **420**, 420–425.

